Repligen Corporation (RGEN) Stock

Repligen Corporation specializes in the development and global commercialization of advanced bioprocessing technologies and systems essential for biological drug manufacturing across North America, Europe, the Asia Pacific, and other international markets. The company's extensive product portfolio includes Protein A ligands, crucial binding components used in Protein A affinity chromatography resins, as well as cell culture growth factors that support biologic production processes.

Central to Repligen's offerings are its chromatography products, featuring OPUS pre-packed columns utilized in biologics purification, alongside smaller-scale OPUS columns designed for high throughput process development screening, viral clearance validation studies, and chromatography process scale-down validations. The company also provides ELISA test kits and chromatography resins under the CaptivA brand to further support bioprocessing applications.

Repligen Corporation is a leader in filtration technologies, offering a range of innovative products including XCell Alternating Tangential Flow systems for upstream perfusion and cell culture processing, TangenX flat sheet cassettes for biologic drug concentration and formulation, and KrosFlo systems for tangential flow filtration and depth filtration. Additionally, its Spectra/Por laboratory and process dialysis products, alongside SpectraFlo dynamic dialysis systems, play critical roles in enhancing purification and separation processes.

The company also specializes in process analytics solutions, featuring slope spectroscopy systems branded as SoloVPE, FlowVPE, and FlowVPX. These systems provide essential analytical capabilities that optimize bioprocess monitoring and control. Repligen Corporation serves a diverse customer base including life sciences, biopharmaceutical, and diagnostic companies, as well as contract manufacturing organizations, driving innovation and efficiency in the global bioprocessing industry.